Green Cross to Form Cell Therapy Company in China

Green Cross, a South Korean biopharma, signed a MOU earlier this month with China's Guizhou provincial government to build a cell therapy manufacturing and distributing center in Guizhou, a southwestern province of China. The company offers a portfolio of approved and investigational cell therapy projects including T cell, NK cell, dendritic cell and stem cells. As a reason for the investment, Green Cross cited the increasing global interest in cell therapy treatments for serious diseases. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.